Austin, Texas, and Raleigh, N.C., June 21, 2018 — Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Elligo Health Research, the only platform that brings clinical research direct to clinical health care, are entering a strategic collaboration to mobilize a system of accelerated research to reach real-world patients. Both companies share a vision to evolve the clinical trial paradigm to speed the delivery of biopharmaceutical therapies to market.
Syneos Health is a top three Contract Research Organization (CRO) that combines comprehensive and integrated outsourcing solutions for both clinical development and commercialization. Elligo Health Research deploys an approach that improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients.
Applying its Goes Direct® approach, Elligo identifies patients for clinical trials using electronic health records and then provides their physicians with the infrastructure to conduct the research in their own practices. This platform enables research at practices that historically would not have had the infrastructure to conduct clinical research. Syneos Health will collaborate with Elligo to pilot new ways of quickly finding patients to enlist them in clinical trial research.
The collaboration will seek to build a centrally managed infrastructure and regulatory research system around physicians and patients who have not typically been accessible in traditional sites. This could include deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden and focusing the experience around the patient.
The ability to bring clinical research to underrepresented populations through community medical practices, evolving from a location-bound approach, to a centrally managed systemic approach, redefines the clinical trial site footprint. This effort should improve quality, reduce timelines and save costs.
“Our biopharma acceleration model is designed to completely surround the patient, caregiver or any stakeholder with the most relevant solutions to make the clinical trial process easier and more accessible. Our collaboration with Elligo allows us to do just that,” said Alistair Macdonald, chief executive officer, Syneos Health. “By leveraging data, technology and trusted physician relationships, we believe we can radically reduce enrollment times and impact health outcomes on behalf of our customers.”
“We are thrilled to collaborate with Syneos Health to create a system of accelerated research that expands our vision of engaging the patient and physician in clinical research,” said John Potthoff, Ph.D., chief executive officer, Elligo. “Not only are we maximizing clinical trial process efficiencies, we’re transforming the clinical trial paradigm with deeper insights and more actionable real-world evidence.”
To learn more about how Syneos Health and Elligo are advancing clinical research, visit syneoshealth.com and elligodirect.com. Also, sign up to receive information about the 2019 Bridging Clinical Research and Clinical Health Care Collaborative, an event sponsored by Syneos Health and Elligo to strengthen the connection between clinical research and health care.
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.
About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the integration of the Company’s business with the business of inVentiv Health and its operation of the combined business following the closing of the Merger; the Company’s ability to maintain or generate new business awards; the Company’s ability to increase its market share, grow its business, and execute its growth strategies; the Company’s backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; the impact of adoption of the new accounting standard of recognizing revenue from customers; the impact of the Tax Act; the Company’s ability to adequately price its contracts and not overrun cost estimates; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; fluctuations in the Company’s financial results; reliance on key personnel; customer or therapeutic area concentration; and the other risk factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and other SEC filings, copies of which are available free of charge on the Company’s website at investor.syneoshealth.com. Syneos Health assumes no obligation and does not intend to update these forward-looking statements, except as required by law.